Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Dulaglutide, SGLT-2 Inhibitors, and Finerenone Triple Therapy in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease: A Multicenter, Prospective, Randomized Controlled Study

NCT07537088 is registered in ClinicalTrials.gov with First Affiliated Hospital of Wannan Medical College as lead sponsor.

NCT NCT07537088
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07537088 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Dulaglutide, SGLT-2 Inhibitors, and Finerenone Triple Therapy in Chinese Adults With Type 2 Diabetes and Chronic Kidney Disease: A Multicenter, Prospective, Randomized Controlled Study
Lead sponsor
First Affiliated Hospital of Wannan Medical College
Phase
Phase 4
Overall status
Not yet recruiting
Start date
May 31, 2026
Completion date
July 31, 2027
Enrollment
468 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

ckd - chronic kidney disease, t2dm (type 2 diabetes mellitus)